Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors

被引：736

作者：

Hicks, J. K. ^{[1
,2
,3
]}

Bishop, J. R. ^{[4
]}

Sangkuhl, K. ^{[5
]}

Mueller, D. J. ^{[6
,7
]}

Ji, Y. ^{[8
]}

Leckband, S. G. ^{[9
,10
]}

Leeder, J. S. ^{[11
,12
]}

Graham, R. L. ^{[13
]}

Chiulli, D. L. ^{[14
]}

LLerena, A. ^{[15
,16
]}

Skaar, T. C. ^{[17
]}

Scott, S. A. ^{[18
]}

Stingl, J. C. ^{[19
]}

Klein, T. E. ^{[5
]}

Caudle, K. E. ^{[20
]}

Gaedigk, A. ^{[11
,12
]}

机构：

[1] Cleveland Clin, Dept Pharm, Cleveland, OH 44106 USA

[2] Cleveland Clin, Genom Med Inst, Cleveland, OH 44106 USA

[3] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Dept Med, Cleveland, OH 44106 USA

[4] Univ Minnesota, Coll Pharm, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA

[5] Stanford Univ, Dept Genet, Stanford, CA 94305 USA

[6] Ctr Addict & Mental Hlth, Campbell Family Mental Hlth Res Inst, Toronto, ON, Canada

[7] Univ Toronto, Dept Psychiat, Toronto, ON, Canada

[8] Mayo Clin, Div Lab Genet, Dept Lab Med & Pathol, Rochester, MN USA

[9] Univ Calif San Diego, Vet Affairs San Diego Healthcare Syst, Mental Hlth Care Line, Skaggs Sch Pharm & Pharmaceut Sci, San Diego, CA 92103 USA

[10] Dept Psychiat, San Diego, CA USA

[11] Childrens Mercy Hosp, Div Clin Pharmacol Toxicol & Innovat Therapeut, Kansas City, MO 64108 USA

[12] Univ Missouri, Dept Pediat, Kansas City, MO 64110 USA

[13] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA

[14] Vet Affairs Palo Alto Hlth Care Syst, San Jose Div, San Jose, CA USA

[15] Extremadura Univ Hosp, CICAB Clin Res Ctr, Badajoz, Spain

[16] Sch Med, Badajoz, Spain

[17] Indiana Univ Sch Med, Dept Med, Div Clin Pharmacol, Indianapolis, IN 46202 USA

[18] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA

[19] Fed Inst Drugs & Med Devices, Bonn, Germany

[20] St Jude Childrens Res Hosp, Dept Pharmaceut Sci, Memphis, TN 38105 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2015年 / 98卷 / 02期

基金：

美国国家卫生研究院;

关键词：

PLASMA-CONCENTRATIONS; PSYCHIATRIC-PATIENTS; ANTIDEPRESSANT TREATMENT; PERSONALIZED MEDICINE; SERUM CONCENTRATIONS; GENETIC-VARIABILITY; PAROXETINE; UPDATE; POLYMORPHISMS; METABOLISM;

D O I：

10.1002/cpt.147

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).

引用

页码：127 / 134

页数：8

共 36 条

[1] Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy [J].

Altar, C. Anthony ;

Hornberger, John ;

Shewade, Ashwini ;

Cruz, Victor ;

Garrison, Jill ;

Mrazek, David .

INTERNATIONAL REVIEW OF PSYCHIATRY, 2013, 25 (05) :509-533

[2] Venlafaxine or a second SSRI: Switching after treatment failure with an SSRI among depressed inpatients: A retrospective analysis [J].

Barak, Yoram ;

Swartz, Marnina ;

Baruch, Yehuda .

PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2011, 35 (07) :1744-1747

[3] Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: Comparison with fluoxetine and quinidine [J].

Bertelsen, KM ;

Venkatakrishnan, K ;

Von Moltke, LL ;

Obach, RS ;

Greenblatt, DJ .

DRUG METABOLISM AND DISPOSITION, 2003, 31 (03) :289-293

[4] Ontogeny of dextromethorphan O- and N-demethylation in the first year of life [J].

Blake, M. J. ;

Gaedigk, A. ;

Pearce, R. E. ;

Bomgaars, L. R. ;

Christensen, M. L. ;

Stowe, C. ;

James, L. P. ;

Wilson, J. T. ;

Kearns, G. L. ;

Leeder, J. S. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 (04) :510-516

[5] Pharmacogenetics of Antipsychotics [J].

Brandl, Eva J. ;

Kennedy, James L. ;

Mueller, Daniel J. .

CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 2014, 59 (02) :76-88

[6] Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity [J].

Carrillo, JA ;

Dahl, ML ;

Svensson, JO ;

Alm, C ;

Rodriguez, I ;

Bertilsson, L .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (02) :183-190

[7] Polymorphisms in the CYP 2D6 gene: Association with plasma concentrations of fluoxetine and paroxetine [J].

Charlier, C ;

Broly, F ;

Lhermitte, M ;

Pinto, E ;

Ansseau, M ;

Plomteux, G .

THERAPEUTIC DRUG MONITORING, 2003, 25 (06) :738-742

[8] Estimation of CYP2D6*10 genotypes on citalopram disposition in Chinese subjects by population pharmacokinetic assay [J].

Chen, B. ;

Xu, Y. ;

Jiang, T. ;

Feng, R. ;

Sun, J. ;

Zhang, W. ;

Yang, W. ;

Li, J. ;

Adeniyi, O. ;

Chen, H. .

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2013, 38 (06) :504-511

[9] Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update [J].

Crews, K. R. ;

Gaedigk, A. ;

Dunnenberger, H. M. ;

Leeder, J. S. ;

Klein, T. E. ;

Caudle, K. E. ;

Haidar, C. E. ;

Shen, D. D. ;

Callaghan, J. T. ;

Sadhasivam, S. ;

Prows, C. A. ;

Kharasch, E. D. ;

Skaar, T. C. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (04) :376-382

[10] Evaluation of the influence of sex and CYP2C19 and CYP2D6 polymorphisms in the disposition of citalopram [J].

Fudio, Salvador ;

Borobia, Alberto M. ;

Pinana, Enrique ;

Ramirez, Elena ;

Tabares, Beatriz ;

Guerra, Pedro ;

Carcas, Antonio ;

Frias, Jesus .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2010, 626 (2-3) :200-204

← 1 2 3 4 →